Business Context and Reporting Period
Company: SeaStar Medical Holding Corp (ICU)
Filing Type: Form 8-K (Current Report)
Date of Report: July 10, 2025
Event: Entry into a Material Definitive Agreement for a registered direct offering and concurrent private placement of equity securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Securities Issued:
- 4,841,232 shares of Common Stock.
- 401,232 Pre-Funded Warrants (exercise price $0.001).
- 5,242,464 Common Warrants (exercise price $0.638).
- Offering Prices:
- Combined price per Share and Common Warrant: $0.763.
- Combined price per Pre-Funded Warrant and Common Warrant: $0.762.
- Net Proceeds: Approximately $3.6 million (after deducting placement agent fees and offering expenses).
- Placement Agent Fees:
- Cash fee: 7.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Expense allowance: $25,000.
- Legal reimbursement: Up to $50,000.
- Closing fee: $15,950.
- Placement Agent Warrants: 366,972 shares (exercise price $0.9538).
Operational Financials: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. These are not reported in this specific 8-K.
Material Changes and Covenants
Capital Structure Change: The transaction significantly increases the number of outstanding shares and warrants, subject to beneficial ownership limitations (4.99% or 9.99% caps).
Lock-Up Provisions:
- 45-Day Lock-Up: The Company agreed not to issue or announce the issuance of Common Stock or convertible securities for 45 days post-closing, with certain exceptions.
- 6-Month Variable Rate Restriction: The Company agreed not to effect variable rate transactions for six months post-closing.
Outlook, Risks, and Use of Proceeds
Use of Proceeds: Net proceeds are intended for general corporate purposes, including costs and expenses associated with being a public company.
Closing Date: Expected on July 11, 2025.
Risks and Contingencies:
- Dilution: The issuance of shares and warrants will dilute existing shareholders.
- Warrant Exercise: Common Warrants expire on the fifth anniversary of the registration statement effective date; Pre-Funded Warrants do not expire.
- Registration: The Company must file a registration statement for the resale of Common Warrant Shares and Placement Agent Warrant Shares within 30 calendar days after June 10, 2025.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received on July 11, 2025.
- Confirm the updated share count and fully diluted capitalization post-offering.
- Review the specific terms of the "variable rate transaction" restriction to understand future financing limitations.
- Monitor the filing of the registration statement for the resale of warrant shares as required within the 30-day window.
- Assess the impact of the $3.6 million cash infusion on the company's runway given its current burn rate (not disclosed in this filing).